Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Octreotide Clear all
Terminated Phase 1Phase 2 Interventional

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

NCT00884715
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Octreotide
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Iowa City, Iowa • Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

NCT05361668
View directory record Official record
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas
Interventions
Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Newport Beach, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 3 Interventional

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002864
View directory record Official record
Conditions
Breast Cancer
Interventions
octreotide acetate, tamoxifen citrate
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

NCT00002779
View directory record Official record
Conditions
Lymphoma
Interventions
fludarabine phosphate, octreotide acetate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

NCT01412424
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

NCT01619865
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
Interventions
68Ga-DOTATOC PET/CT
Drug
Lead sponsor
Sue O'Dorisio
Other
Eligibility
2 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Octreotide on Saliva

NCT05340192
View directory record Official record
Conditions
Healthy
Interventions
Octreotide 1 MG/ML
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions
AMG 706, octreotide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
112
States / cities
Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Glucagon Administration on Energy Expenditure

NCT02237053
View directory record Official record
Conditions
Hyperglucagonemia, Obesity
Interventions
Glucagon, Octreotide, Placebo, Insulin
Drug · Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 4 Interventional

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

NCT00068042
View directory record Official record
Conditions
Acromegaly
Interventions
Pegvisomant, Sandostatin LAR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2008 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

NCT03289741
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Octreotide, LAR Lanreotide, Questionnaires
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

NCT01121939
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Bevacizumab, Pertuzumab, Sandostatin LAR® Depot
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00130845
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 2, 2026, 5:09 PM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

NCT03792555
View directory record Official record
Conditions
Acromegaly
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796
View directory record Official record
Conditions
Liver, Cancer
Interventions
Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

Surgical Debulking of Pituitary Adenomas

NCT01371643
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
Octreotide LAR, transsphenoidal surgery
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 2, 2026, 5:09 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625
View directory record Official record
Conditions
Acromegaly
Interventions
Debio 4126, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

Effect of Octreotide on the Colonic Motility in Pediatric Patients

NCT01917773
View directory record Official record
Conditions
Colonic Motility Index, Constipation
Interventions
Octreotide, Bisacodyl
Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 2, 2026, 5:09 PM EDT
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 2, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

NCT00003283
View directory record Official record
Conditions
Thymoma and Thymic Carcinoma
Interventions
octreotide acetate, prednisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
24
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 2, 2026, 5:09 PM EDT